Vadastuximab disitamab vedotin antibody-drug compound representing a important advancement in the approach of acute myeloid leukemia (AML). This pioneering therapy specifically targets CD33, a marker https://socialrus.com/story24585907/vadastuximab-a-deep-investigation-into-cd33-specific-therapy